“Elderly ACS Patients with CYP2C19 LOF Variants on PCI Have Increased Adverse Clinical Events and Bleeding with Ticagrelor vs Clopidogrel”

https://pubmed.ncbi.nlm.nih.gov/38114408

The study found that among elderly ACS patients with CYP2C19 LOF variants who had undergone PCI, those treated with ticagrelor had a significant increase in net adverse clinical events and bleeding, with similar ischemic events compared to those treated with clopidogrel.